|Bid||335.50 x 0|
|Ask||335.60 x 0|
|Day's Range||335.00 - 339.80|
|52 Week Range||225.60 - 339.80|
|PE Ratio (TTM)||21.79|
|Forward Dividend & Yield||1.12 (2.34%)|
|1y Target Est||320.16|
Partnerships with cities to change the way we manage our health are a long-term solution to the obesity and diabetes epidemic, Jesper Brandgaard said.
Bagsværd, Denmark, 11 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.
The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza. Novo Nordisk is also developing an oral form of semaglutide.
Bagsværd, Denmark, 5 December 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic ® (semaglutide injection). Ozempic ® is indicated as an adjunct to ...
MÅLØV, Denmark, Nov 21 (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States. The world's largest maker of diabetes drugs said on Tuesday it would aim to develop medicines that treat obesity - a major cause of diabetes - at least as effectively as surgery.
Bagsværd, Denmark, 21 November 2017 - Novo Nordisk will today host a Capital Markets Day where the company will provide updates on its R&D and commercial strategy as well as current market dynamics. Novo ...
Bagsværd, Denmark, 20 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Emerson (EMR) recently clinched an automation systems and services contract for Novo Nordisk's drug manufacturing facility in Clayton.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
President Donald Trump on Monday said he is nominating former pharmaceutical executive and industry lobbyist Alex Azar to serve as U.S. Health and Human Services secretary, saying Azar would push to lower the price of medicines. Republicans as well as the lead lobby groups for drugmakers and health insurers welcomed Azar as an experienced hand who could help overhaul the world's most costly healthcare system.
The number of people living with diabetes has tripled since 2000, pushing the global cost of the disease to $850 billion a year, medical experts said on Tuesday. The vast majority of those affected have type 2 diabetes, which is linked to obesity and lack of exercise, and the epidemic is spreading particularly fast in poorer countries as people adopt Western diets and urban lifestyles. The latest estimates from the International Diabetes Federation mean that one in 11 adults worldwide have the condition, which occurs when the amount of sugar in the blood is too high.
Bagsværd, Denmark, 6 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council ...
Allergan and Novo Nordisk offered Street-topping adjusted profit in the third quarter, though Allergan's sales were just in line.
Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.
Drugmaker Novo Nordisk forecast only muted growth in 2018 and warned that draft legislation in some U.S. states to make pricing more transparent could impact business in its largest market. The warning over U.S. state legislation comes after fears that President Donald Trump's healthcare policies could hurt the industry have diminished somewhat during the year. "Trump has repeated a number of times that he believes the industry gets away with murder, obviously we don't agree," said Lars Fruergaard Jorgensen, chief executive of the Danish company.
Drugmaker Novo Nordisk said on Wednesday that new legislation being prepared in some U.S. states to improve pricing transparency could potentially impact business in its key market. "If the transparency ...
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's top maker of diabetes drugs, posted third-quarter operating profit slightly above forecasts on Wednesday, and said it expected low to mid single-digit ...